Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Up 2,371.8% in February

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the recipient of a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 46,346 shares, an increase of 2,371.8% from the February 12th total of 1,875 shares. Based on an average daily volume of 20,337 shares, the short-interest ratio is presently 2.3 days. Approximately 1.4% of the shares of the stock are short sold. Approximately 1.4% of the shares of the stock are short sold. Based on an average daily volume of 20,337 shares, the short-interest ratio is presently 2.3 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC lifted its stake in Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,630 shares of the company’s stock after buying an additional 17,031 shares during the period. Citadel Advisors LLC owned approximately 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent SEC filing. 58.41% of the stock is currently owned by institutional investors.

Scinai Immunotherapeutics Stock Performance

Shares of Scinai Immunotherapeutics stock opened at $0.75 on Wednesday. Scinai Immunotherapeutics has a 52-week low of $0.61 and a 52-week high of $6.18. The company has a fifty day moving average of $0.84 and a 200-day moving average of $1.10. The stock has a market capitalization of $2.60 million, a price-to-earnings ratio of -0.08 and a beta of 1.89.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Scinai Immunotherapeutics presently has an average rating of “Sell”.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.